NeuroMetrix, Inc. Announces Date for 2013 Second Quarter Financial Results
WALTHAM, Mass. -- July 17, 2013
NeuroMetrix, Inc. (Nasdaq: NURO), today said it plans to issue its 2013 second
quarter financial results before the opening of the market on July 25, 2013.
The Company will host a conference call at 8:00 a.m., Eastern Time on July 25,
2013 to discuss its financial results as well as business developments
affecting the Company.
The conference call may be accessed in the United States by dialing
866-510-0707 and using the confirmation code 18430936. Internationally, the
conference call may be accessed by dialing 617-597-5376 and using the same
confirmation code. The earnings press release and accompanying condensed
financial statements will be accessible from the Company's website at
www.neurometrix.com under the "Investors" tab.
A replay of the conference call will be available starting two hours after the
call by dialing 888-286-8010, domestically and 617-801-6888, internationally.
The confirmation code to access the replay is 19088827. The replay will be
available for two weeks after the conference call.
NeuroMetrixis a medical device company that develops and markets home use and
point-of-care devices for the treatment and management of diabetic
neuropathies, which affect over 50% of people with diabetes. If left
untreated, diabetic neuropathies trigger foot ulcers that may require
amputation and cause disabling chronic pain. The annual cost of diabetic
neuropathies has been estimated at$14 billionintheUnited States. The
company’s products are used by physicians and managed care organizations to
optimize patient care and reduce healthcare costs. The company markets the
SENSUS^™ Pain Management System for treating chronic pain, focusing on
physicians managing patients with painful diabetic neuropathy and similar
peripheral neuropathies. The company also markets the
NC-stat^®DPNCheck^®device, which is a rapid, accurate, and quantitative
point-of-care test for diabetic neuropathy. This product is used to detect
diabetic neuropathy at an early stage and to guide treatment. For more
information, please visithttp://www.neurometrix.com.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.